Today news
The same in other media
Serum Institute begins production of Novavax covid vaccine in Pune
Reading now: 516
@Novavax) at our facility, here in Pune. pic.twitter.com/FqoVTUa1nO Novavax's vaccine exhibited a 90.4 per cent overall efficacy in Phase-3 clinical trials.
That puts it in the same bracket as two of the frontline vaccines being used in the US and European countries, the ones produced by Pfizer-BioNTech and Moderna, which had efficacy rates of 91.3 per cent and 90 per cent in Phase 3 trials, respectively.
The Centre said that recently said that Novavax Covid vaccine efficacy data in a large trial are promising and that clinical trials are being conducted and are in an advanced stage of completion in India. "What we're learning from data available in the public domain that this vaccine is very safe and highly effective.
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
COVID-19
United States
|
Cases: 46 252 513
Deaths: 750 423
Recovered: 0
|
India
|
Cases: 34 321 025
Deaths: 459 652
Recovered: 0
|
Brazil
|
Cases: 21 835 785
Deaths: 608 235
Recovered: 0
|
United Kingdom
|
Cases: 9 215 683
Deaths: 141 607
Recovered: 0
|
Russia
|
Cases: 8 494 589
Deaths: 237 619
Recovered: 0
|